The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial-Reference-Cited by-同舟云学术

The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial

Published:2014-05 Issue:3 Volume:28 Page:323-327
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

Black R. Neil A.,Ennis Cieran N.,Young Ian S.,Hunter Steven J.,Atkinson A. Brew,Bell Patrick M.

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference30 articles.

1. Banting lecture 1988. Role of insulin resistance in human disease;Reaven;Diabetes,1988

2. The myth of the metabolic syndrome;Gale;Diabetologia,2005

3. Peroxisome proliferator-activated receptors: Nuclear control of metabolism;Desvergne;Endocrine Reviews,1999

4. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus;Randle;Lancet,1963

5. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes;Cline;New England Journal of Medicine,1999

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The natural compounds, Magnolol or Honokiol, promote adipose tissue browning and resist obesity through modulating PPARα/γ activity;European Journal of Pharmacology;2024-04

2. Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome;Heart and Vessels;2024-02-23

3. Benefits and harms of fibrate therapy in patients with type 2 diabetes: a systematic review and meta-analysis;Endocrine;2023-05-29

4. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans;Toxicological Sciences;2023-01-11

5. PPARα: An emerging target of metabolic syndrome, neurodegenerative and cardiovascular diseases;Frontiers in Endocrinology;2022-12-16